IL1B and PFAPA syndrome: A further proof for the role of IL-1β derives from clinical responsiveness to IL-1β inhibition: a small uncontrolled study has suggested that treatment with anakinra reduces the duration of acute flares in PFAPA patients [139], and an adult case of PFAPA syndrome refractory to conventional therapy who was responsive to anakinra has also been reported [140].